J Cancer 2022; 13(3):943-950. doi:10.7150/jca.66959 This issue Cite
Research Paper
1. Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, 300052, China.
2. Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin, 300052, China.
Objective: To investigate the role of miR-506-3p in ovarian cancer (OvCa) metastasis.
Methods: We overexpressed miR-506-3p in OvCa cells, and cell migration and invasion capacities were assessed in vitro using Transwell assays and wound healing assay. EZH2 is a target of miR-506-3p. We overexpressed and knocked down EZH2 in SKOV3 cells, and assessed its impact on cell migration and invasion. The orthotopic OvCa mouse models were conducted to confirm the role of miR-506-3p in OvCa metastasis.
Results: In this research, we found that miR-506-3p reduced EZH2 expression and obviously suppressed the cell migration and invasion in ovarian cancer (OvCa). Moreover, the knockout of EZH2 mimicked the effect of miR-506-3p on invasion and migration, whereas EZH2 overexpression rescued the inhibitory effect of miR-506-3p. The orthotopic OvCa mouse models and clinical cases also confirmed the negative correlation between miR-506-3p and EZH2 in OvCa
Conclusions: MiR-506-3p can suppress cell migration and invasion by targeting EZH2 in OvCa. Our study provides evidence supporting miR-506-3p-based therapy in OvCa.
Keywords: miR-506-3p, EZH2, ovarian cancer, metastasis